A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Nammi Therapeutics Inc
Jazz Pharmaceuticals
Zumutor Biologics Inc.
Astellas Pharma Inc
SystImmune Inc.
Merck Sharp & Dohme LLC
Genmab
Myeloid Therapeutics
Avacta Life Sciences Ltd
Ocellaris Pharma, Inc.
Innate Pharma
Dren Bio
Tanabe Pharma America, Inc.
Massive Bio, Inc.
ITM Oncologics GmbH
Nurix Therapeutics, Inc.
Exelixis
Incyte Corporation
Xencor, Inc.
NextPoint Therapeutics, Inc.
OncoC4, Inc.
Monopar Therapeutics
Monopar Therapeutics
Klus Pharma Inc.
Orion Biotechnology Polska Sp. z o.o.
Cofactor Genomics, Inc.
Daiichi Sankyo
RAPT Therapeutics, Inc.
Cybrexa Therapeutics
Carisma Therapeutics Inc
Vincerx Pharma, Inc.
Salubris Biotherapeutics Inc
Xencor, Inc.
Pliant Therapeutics, Inc.
NextCure, Inc.
pharmaand GmbH
Atreca, Inc.
Fate Therapeutics
OncoNano Medicine, Inc.
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Nektar Therapeutics
Rubius Therapeutics
Xencor, Inc.
Incyte Corporation
Hoffmann-La Roche
PACT Pharma, Inc.
Gossamer Bio Inc.